Phospho-p73 (Thr86) Antibody - #AF8296

Figure 5. DR5 is required for the antitumor activity of combining Palbo and TRAIL or 5-FU in mice. (A)-(C) Nude mice with established WT or DR5-KO HCT116 xenografts were treated with TRAIL (i.p.; 100 μg/mice every other day), Palbo (oral gavage;150 mg/kg daily), or their combination as indicated. (A) Tumor volume at indicated time points with statistical significance for indicated comparisons (N=6 in each group). (B) Western blotting of DR5 and p-p73 (Thr86) in randomly selected WT tumors treated as in (A) for 4 consecutive days. (C) Tumor sections from mice treated as in (B) were analyzed for apoptosis by active caspase 3 staining (left panel) and quantification (right panel). Scale bars: 25 μm. (D)-(F) Nude mice with established WT or DR5-KO HCT116 xenografts were treated with 5-FU (i.p.; 25 mg/kg every other day), Palbo (oral gavage;150 mg/kg daily), or their combination as indicated. (D) Tumor volume at indicated time points with statistical significance for indicated comparisons (N=6 in each group). (E) Western blotting of DR5 in randomly selected WT tumors treated as in (D) for 4 consecutive days. (F) Tumor sections from mice treated as in (E) were analyzed for apoptosis by active caspase 3 staining (left panel) and quantification (right panel). Scale bars: 25 μm. In (C) and (F), arrows indicate examples of positive signals. Bar graphs show results of 300 cells in each mouse (N=3 in each group). *, P < 0.05; **, P < 0.01; ***, P < 0.001.